AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) – Equities research analysts at HC Wainwright boosted their Q3 2024 earnings per share estimates for AEON Biopharma in a research report issued to clients and investors on Wednesday, August 14th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.16) per share for the quarter, up from their prior forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.77) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.70) EPS and FY2027 earnings at ($0.42) EPS.
AEON Biopharma Stock Performance
AEON opened at $1.02 on Friday. AEON Biopharma has a 1-year low of $0.80 and a 1-year high of $17.17. The firm has a 50-day moving average price of $1.46 and a two-hundred day moving average price of $5.23.
Institutional Trading of AEON Biopharma
AEON Biopharma Company Profile
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
See Also
- Five stocks we like better than AEON Biopharma
- How to Invest in Biotech Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 8/12 – 8/16
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.